Olutasidenib is currently being investigated in a phase 1/2 open label, multicenter study in R/R or treatment naive IDH1-mutated AML or MDS patients, either as monotherapy or in combination with azacitidine (NCT02719574). The gene discussed is IDH1; the disease is acute myeloid leukemia.